United Kingdom · Chemicals startup

Exosect Limited

Exosect Limited is a UK-based pest-management technology company founded in 2001 as a spin-out from the University of Southampton.

Funding reportedLast round: Undisclosed round

ChemicalsWinchester, United Kingdom

About Exosect Limited

Exosect Limited is a UK-based pest-management technology company founded in 2001 as a spin-out from the University of Southampton.

Headquartered in Winchester, Hampshire, Exosect specializes in developing innovative pest control and delivery-platform solutions for agriculture, public health, and animal health. The company focuses on enhancing the delivery of pest-control active ingredients to tackle challenges like pest resistance and regulatory constraints. Exosect's notable products include Entostat, an electrostatically charged micro-powder for microencapsulating synthetic active ingredients, and Entomag, a ferrous micro-powder designed for targeted delivery in public health applications. The company also developed a bee-health treatment for varroa mite control, which was acquired by Bayer CropScience. Exosect's technologies are aimed at improving pest control efficacy across various sectors.

What company datasets say Exosect Limited raised

Funding, as reported

Reported in all13.5Min the source's currency
Rounds8
Last roundUndisclosed round
Last round size2.1M
Last round dateJan 2015
Investors listed5

The company, in detail

What they build

Known for

serviceschemical manufacturingchemicalsb2b

Built with from their website

Microsoft ExchangeMicrosoft AzureMicrosoft Azure HostingMicrosoft 365 Apps & ServicesMobile FriendlyWebmailSendgridMicrosoft Exchange OnlineRemoteMicrosoft 365

+3 more

Azure App ServiceOutlookTwilio SendGrid Email API

Sector
Chemicals
Industry code
NAICS 541714, SIC 0100
Region
England
Revenue
10M a year, as listed
Full record
Every detail in the company directory

Chemicals in United Kingdom

Startups like it

Is this your company?

Add your raise, your deck and your story, and put Exosect Limited in front of investors. Or tell us what we have wrong.